Insights

Insight
February 2020

Do child QALYs = adult QALYs? Five reasons why they might not

Insight
December 2019

25 Years of the Cost Effectiveness Acceptability Curve

Insight
October 2019

NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study

Insight
September 2019

A Market-based International Reference Price Index: Solution or Contradiction?

Insight
May 2019

We Asked, You Answered: Reflections on the First Round of MVAC Feedback

Insight
March 2019

HTA in Japan: Failing to Meet International Good Practice?

Insight
September 2018

As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?

Insight
September 2018

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

Insight
August 2018

NICE Recommendation Highlights Role of Social Value Judgements

Insight
February 2018

Alan Maynard – Alas No More

Insight
April 2017

The Long-term Sustainability of the NHS and Adult Social Care

Insight
January 2016

5 Things You Should Do with EQ-5D Data

Newsroom

The latest news and comment from OHE experts

Read Now

Subscribe To Our Newsletter

Our monthly Bulletin highlights our work alongside the latest from across health economics and health care.

News and Insights

Latest Research & Publications

A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Personalised Medicine: is it an Oil-Rush or Oil-Spill?

Indication-Based Pricing (IBP) Consultation Report

Closing the ‘Know-Do’ Gap for Health Systems Reform at the Policy Level

The Evolution of US Policy Responses to the Opioid Epidemic

All Publications

Filter results by

Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool

R&D For New Drugs To Tackle AMR Is A High Return Investment For All EU Member States

Filter results by

Do child QALYs = adult QALYs? Five reasons why they might not

25 Years of the Cost Effectiveness Acceptability Curve

NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study

A Market-based International Reference Price Index: Solution or Contradiction?

We Asked, You Answered: Reflections on the First Round of MVAC Feedback

HTA in Japan: Failing to Meet International Good Practice?

As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

NICE Recommendation Highlights Role of Social Value Judgements

Alan Maynard – Alas No More

The Long-term Sustainability of the NHS and Adult Social Care

5 Things You Should Do with EQ-5D Data

Newsroom

Subscribe To Our Newsletter

Share on Mastodon